<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033250</url>
  </required_header>
  <id_info>
    <org_study_id>0117-19-RMB CTIL</org_study_id>
    <nct_id>NCT04033250</nct_id>
  </id_info>
  <brief_title>Personalized Colonoscopy Preparation for Patients With Risk Factors for Inadequate Preparation</brief_title>
  <official_title>Personalized Colonoscopy Preparation for Patients With Risk Factors for Inadequate Preparation: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adequate bowel preparation is one of the most important quality measures in colonoscopy.
      Previous studies identified several factors associated with inadequate bowel preparation
      (IBP). No study has attempted to assign a different regimen to patients based on the presence
      of risk factors for inadequate bowel preparation.

      The aim of the study is to check if a personalized bowel preparation regimen based on risk
      factors for IBP, will lead to an overall improvement in bowel preparation during colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved bowel preparation</measure>
    <time_frame>Index colonoscopy</time_frame>
    <description>Boston Bowel Preparation Scale at index colonoscopy will be measured. The grading is between 1 and 3 for each segment of colon (ascending, transverse, descending) where 1 is poor and 3 is excellent (subscale). The final score is between 3 and 9 summing up the scores for each segment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Inadequate Preparation for Colonoscopy; Personalized Colonoscopy Preparation</condition>
  <arm_group>
    <arm_group_label>Interventional arm (group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with risk factors for IBP who will receive &quot;intensified&quot; bowel preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm (group B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with risk factors for IBP who will receive standard bowel preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm (group c)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without risk factors for IPB who will receive standard bowel preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure</intervention_name>
    <description>Bowel preparation</description>
    <arm_group_label>Control arm (group B)</arm_group_label>
    <arm_group_label>Control arm (group c)</arm_group_label>
    <arm_group_label>Interventional arm (group A)</arm_group_label>
    <other_name>Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previous IBP

          -  concurrent medical conditions (e.g. diabetes, constipation)

          -  medications (e.g. opioids and tricyclic antidepressants)

        Exclusion Criteria:

          -  previous colonic resection

          -  patients with IBD

          -  active CRC

          -  chronic kidney disease at any stage

          -  congestive heart failure at any stage

          -  liver cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Klein, MD</last_name>
    <phone>+972-4-7773625</phone>
    <email>am_klein@rmc.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Amir Klein MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisacodyl</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

